Anatomy & Physiology: Current Research
Open Access

Abstract

etoposide on h9c2 cardiomyoblasts against doxorubicin initiated cardiotoxicity

Suad Aden

Foundation: Doxorubicin (DOX), a broadly utilized anticancer medication, has been related with cardiotoxicity. As of late, DOX-prompted cardiotoxicity has been ascribed to topoisomerase II (TOPII)- β articulation and movement. In our examination, we researched the impact of restraining TOPII in weakening the DOX actuated cardiotoxicity.

 

Strategy: H9c2 cardiomyoblasts were treated with 1 or 2 µM DOX (+/ - ) 1 µM ETO. Cardiotoxicity was surveyed by inspecting cell reasonability utilizing the MTT measure, hypertrophy of gem violet recolored cardiomyoblasts and ROS creation.

 

Results: DOX instigated a portion subordinate expansion in cardiotoxicity as demonstrated by the huge decrease in cell suitability (71.77 ± 9.25% 2 µM DOX versus 100% control

Published Date: 2020-11-30; Received Date: 2020-11-16